Skip to main content
. 2018 Aug 30;10(3):142. doi: 10.3390/pharmaceutics10030142

Figure 5.

Figure 5

Profiles of mean (±SE) plasma concentration versus time after administration of MK-A formulations (15 mpk) to pentagastrin-pretreated male Beagle dogs (n = 3 or 6).